Cancer immunotherapy: An evidence-based overview and implications for practice Journal Article
| Authors: | Bayer, V.; Amaya, B.; Baniewicz, D.; Callahan, C.; Marsh, L.; McCoy, A. S. |
| Article Title: | Cancer immunotherapy: An evidence-based overview and implications for practice |
| Abstract: | BACKGROUND: Significant research progress has been made in immunotherapies since the mid-1990s, and this rapid evolution necessitates evidence-based education on immunotherapies, their pathophysiology, and their toxicities to provide safe, effective care. OBJECTIVES: The aim of this article is to provide an evidence-based overview, with implications for practice, of checkpoint inhibitors, monoclonal antibodies, oncolytic viral therapies, and chimeric antigen receptor T-cell therapies. METHODS: Each immunotherapy category is presented according to the pathophysiology of its immune modulation, the classes of agents within each category, evidence-based toxicities associated with each class, and implications for practice. FINDINGS: Immunotherapies vary in their pathophysiology and offer potential to be highly effective for the management of a wide array of cancer types. Understanding the unique pathophysiology and toxicities is necessary to assess, manage, and provide safe, effective patient-focused care. © 2017, Oncology Nursing Society. All rights reserved. |
| Keywords: | pathophysiology; monoclonal antibodies; immunotherapy; toxicities |
| Journal Title: | Clinical Journal of Oncology Nursing |
| Volume: | 21 |
| Issue: | 2 Suppl. |
| ISSN: | 1092-1095 |
| Publisher: | Oncology Nursing Society (ONS) |
| Date Published: | 2017-04-15 |
| Start Page: | 13 |
| End Page: | 21 |
| Language: | English |
| DOI: | 10.1188/17.cjon.s2.13-21 |
| PROVIDER: | scopus |
| PUBMED: | 28315552 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 August 2017 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work